Several analysts have recently updated their ratings and price targets for Tango Therapeutics (NASDAQ: TNGX):
- 11/10/2026 – Tango Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $65.00 price target on the stock.
- 11/10/2026 – Tango Therapeutics had its price target raised by JPMorgan Chase & Co. from $46.00 to $47.00. They now have an “overweight” rating on the stock.
- 11/10/2026 – Tango Therapeutics had its price target lowered by Wedbush from $45.00 to $40.00. They now have an “outperform” rating on the stock.
- 11/10/2026 – Tango Therapeutics had its price target lowered by HC Wainwright from $68.00 to $67.00. They now have a “buy” rating on the stock.
- 11/4/2026 – Tango Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 10/29/2026 – Tango Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $68.00 price target on the stock.
- 10/27/2026 – Tango Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
- 10/23/2026 – Tango Therapeutics was given a new $55.00 price target by Stifel Nicolaus.
- 10/16/2026 – Tango Therapeutics is now covered by William Blair. They set an “outperform” rating on the stock.
Tango Therapeutics Price Performance
Tango Therapeutics stock opened at $22.11 on Wednesday. The stock’s 50 day moving average is $23.55 and its 200 day moving average is $22.91. Tango Therapeutics, Inc. has a one year low of $7.69 and a one year high of $34.39. The firm has a market cap of $3.75 billion, a P/E ratio of -16.14 and a beta of 1.26.
Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). Equities analysts anticipate that Tango Therapeutics, Inc. will post -1.46 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, insider Adam Crystal sold 5,000 shares of Tango Therapeutics stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the transaction, the insider directly owned 115,743 shares of the company’s stock, valued at approximately $2,893,575. This trade represents a 4.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jessica Newcomb sold 7,031 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $22.42, for a total value of $157,635.02. Following the completion of the transaction, the insider directly owned 52,090 shares in the company, valued at $1,167,857.80. This represents a 11.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 52,231 shares of company stock worth $1,254,029 in the last ninety days. Insiders own 6.50% of the company’s stock.
Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.
Read More
- Five stocks we like better than Tango Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Tango Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
